Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Nets $340M in Public Offering

NEW YORK (GenomeWeb News) – Illumina said today that it has raised net proceeds of $342.6 million in a public stock offering.
The company said that it sold 4,025,000 shares at $87.50 per share in the offering.
Goldman, Sachs was the sole manager of the offering.
Illumina said last week that it plans to use the proceeds from the offering to fund R&D efforts, expand its manufacturing capacity, and for working capital needs. The company said that it may also use the financing to acquire, license, or invest in other businesses, technologies, or products.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.